With US$1.1 billion now allocated for comparative effectiveness research in the United States, a key question is how to use this opportunity to develop a better model for the assessment of health-care value.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Alzheimer’s disease: diagnostics, prognostics and the road to prevention
EPMA Journal Open Access 29 June 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Hughes, B. The comparative effectiveness challenge. Nat Rev Drug Discov 8, 261–263 (2009). https://doi.org/10.1038/nrd2866
Issue Date:
DOI: https://doi.org/10.1038/nrd2866
This article is cited by
-
Therapeutic Index of Anticoagulants for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose–Response Meta-Analysis
Clinical Pharmacology & Therapeutics (2011)
-
Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers
Nature Reviews Drug Discovery (2010)
-
2009 in reflection
Nature Reviews Drug Discovery (2010)
-
News in brief
Nature Reviews Drug Discovery (2010)
-
Alzheimer’s disease: diagnostics, prognostics and the road to prevention
EPMA Journal (2010)